Factors affecting hematologic recovery and infection in high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk solid tumor.
10.3345/kjp.2006.49.10.1079
- Author:
Jung Hyun LEE
1
;
Bo Lyun LEE
;
Soo Hyun LEE
;
Keon Hee YOO
;
Ki Woong SUNG
;
Hye Lim JUNG
;
Eun Joo CHO
;
Hong Hoe KOO
Author Information
1. Department of Pediatrics, Sungkyunkwan University School of Medicine, Seoul, Korea. kwsped@smc.samsung.co.kr
- Publication Type:Original Article
- Keywords:
High-dose chemotherapy;
Autologous hematopoietic stem cell transplantation;
Pediatric solid tumor
- MeSH:
Blood Platelets;
Child;
Drug Therapy*;
Fever;
Hematopoietic Stem Cells;
Humans;
Medical Records;
Neutrophils;
Retrospective Studies;
Stem Cell Transplantation*;
Stem Cells*;
Thiotepa;
Whole-Body Irradiation
- From:Korean Journal of Pediatrics
2006;49(10):1079-1085
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The purpose of this study was to evaluate factors affecting hematologic recovery and infection in high-dose chemotherapy(HDCT) and autologous stem cell transplantation(ASCT) in patients with high-risk solid tumor. METHODS: From January 2004 to December 2005, 72 HDCTs and ASCTs were applied to children with high-risk solid tumor at Samsung Medical Center. Medical records of these 72 HDCTs and ASCTs were retrospectively analyzed. RESULTS: The single most powerful predictor of neutrophil and platelet recovery was the number of transplanted CD34+ cells. The duration of high fever was significantly longer in young patients, in patients treated with total body irradiation and/or thiotepa, and in patients transplanted with lower CD34+ cell dose(<2x10(6)/kg). However, the difference in the duration of high fever according to the number of CD34+ cells was not clinically significant. CONCLUSION: Findings in this study suggest that HDCT and ASCT with low CD34+ cell dose is clinically feasible despite delayed hematologic recovery, especially at a dose >1x10(6)/kg per transplantation. Therefore, it is important not to defer the appropriate time for HDCT for an additional collection of hematopoietic stem cells if the number of collected CD34+ cells is >1x10(6)/kg per transplantation.
